About Medicine OnLine Medicine OnLine Home PageCancer LibrariesDoseCalc OnlineOncology News
Cancer ForumsMedline SearchCancer LinksGlossary

Navelbine

Navelbine Quick Reference Card

Indication

NAVELBINE is indicated as a single agent or in combination with cisplatin for the treatment of ambulatory patients with advanced, unresectable non-small cell lung cancer.

Contraindications

The use of NAVELBINE is contraindicated in patients with a pre-treatment granulocyte count of less than 1000 cells/cubic mm.

Dosage and Administration

Preparation and Administration

  1. Dilute NAVELBINE in syringe to concentration of 1.5 - 3 mg/mL in Normal Saline, D5W or other compatible solutions.
  2. Infuse diluted NAVELBINE i.v. over 6 to 10 minutes into side-arm port of free-flowing IV infusion, either peripherally or in central line. Be sure to infuse NAVELBINE into the side-arm port closest to the free-flowing IV bag.
  3. Flush vein with at least 75 to 125 mL of Normal Saline or D5W.
Administration Precautions

Exercise caution in handling and preparing NAVELBINE solution. As with other toxic compounds, skin reactions may occur with accidental exposure. Use of gloves is recommended. If NAVELBINE solution contacts skin or mucosa, immediately wash thoroughly with soap and water. If accidental contamination of the eye occurs, flush the eye with water immediately and thoroughly.

Injection Site Reactions

Like other vinca alkaloids, NAVELBINE is a moderate vesicant and an irritant to the vein. Some patients may experience erythema, pain at injection site, vein discoloration, and/or chemical phlebitis along the vein proximal to injection site. Proper administration technique is important. If an extravasation occurs, treat according to institutional guidelines.

Adverse Events

Hematologic
The major dose-limiting toxicity of NAVELBINE is hematologic, specifically granulocytopenia, which is predictable at 7-10 days, generally reversible and not cumulative over time, usually does not require growth factor support, and can be managed by a modification in the dose.

Nonhematologic
Nonhematologic adverse effects are usually mild or moderate and include injection site reactions, nausea/vomiting, constipation, fatigue, peripheral neuropathy, diarrhea, and alopecia. Fatigue and injection site reactions were the only nonhematologic events that were of Grade 3-4 intensity in >5% of patients.

Patient Information

Patients should be informed that the major acute toxicities of NAVELBINE are related to bone marrow toxicity, specifically granulocytopenia with increased susceptibility to infection. They should report fever or chills immediately.

How Supplied

50 mg/5 mL single-use vial (NDC 0081-0656-44)

10 mg/1 mL single-use vial (NDC 0081-0656-01)

Storage

Store vials at 2° to 8°C (36° to 46°F) and protect from light.
Do not freeze.

Stability

For further information, call Glaxo Wellcome Inc. Drug Information Service at 1-800-443-6763.


Top | Lung Library Index | Navelbine Index ]

About Medicine OnLine Medicine OnLine Home PageCancer LibrariesDoseCalc OnlineOncology News
Cancer ForumsMedline SearchCancer LinksGlossary